Merus

Merus is a clinical-stage biotechnology company based in the Netherlands that specializes in developing innovative bispecific antibody therapeutics to treat cancer. The company’s proprietary Biclonics® technology platform enables the creation of full-length human bispecific antibodies, which are designed to engage multiple targets and enhance anti-tumor activity. Merus generates revenue through strategic collaborations, licensing agreements, and milestone payments with major pharmaceutical partners such as Incyte and Eli Lilly. Founded in 2003, Merus has advanced several candidates into clinical trials, with a focus on solid tumors and hematologic malignancies. The company’s commitment to scientific innovation and partnerships positions it as a key player in the immuno-oncology field.

Recent Posts by Merus

1-10 of 10